GlaxoSmithKline plc (GSK) Price Target Cut to GBX 1,760

GlaxoSmithKline plc (LON:GSK) had its price objective reduced by equities research analysts at Berenberg Bank from GBX 1,835 ($24.21) to GBX 1,760 ($23.23) in a research note issued on Thursday. The brokerage currently has a “buy” rating on the stock. Berenberg Bank’s target price indicates a potential upside of 29.32% from the company’s current price.

Several other research analysts have also commented on GSK. Citigroup Inc. lowered GlaxoSmithKline plc from a “buy” rating to a “neutral” rating and set a GBX 1,700 ($22.43) price target for the company. in a research report on Wednesday, July 5th. Jefferies Group LLC reiterated a “buy” rating and issued a GBX 1,900 ($25.07) price target on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. J P Morgan Chase & Co reiterated a “neutral” rating and issued a GBX 1,750 ($23.09) price target on shares of GlaxoSmithKline plc in a research report on Thursday, July 13th. Shore Capital reiterated a “hold” rating on shares of GlaxoSmithKline plc in a research report on Friday, July 14th. Finally, Morgan Stanley reiterated an “equal weight” rating and issued a GBX 1,700 ($22.43) price target on shares of GlaxoSmithKline plc in a research report on Tuesday, July 18th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and six have issued a buy rating to the company. GlaxoSmithKline plc has a consensus rating of “Hold” and a consensus target price of GBX 1,619.75 ($21.37).

GlaxoSmithKline plc (LON:GSK) traded up GBX 9.50 ($0.13) on Thursday, reaching GBX 1,361 ($17.96). The company had a trading volume of 7,047,222 shares.

GlaxoSmithKline plc (LON:GSK) last released its quarterly earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.43) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of GBX 31.80 ($0.42) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion during the quarter. GlaxoSmithKline plc had a negative return on equity of 57.19% and a negative net margin of 1.17%.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.com-unik.info/2017/11/04/glaxosmithkline-plc-gsk-price-target-cut-to-gbx-1760.html.

In other GlaxoSmithKline plc news, insider Simon Dingemans acquired 1,076 shares of GlaxoSmithKline plc stock in a transaction that occurred on Thursday, October 12th. The stock was bought at an average price of GBX 1,527 ($20.15) per share, with a total value of £16,430.52 ($21,681.87). Also, insider Urs Rohner acquired 473 shares of GlaxoSmithKline plc stock in a transaction that occurred on Wednesday, October 25th. The stock was acquired at an average cost of GBX 1,518 ($20.03) per share, with a total value of £7,180.14 ($9,474.98). Insiders purchased 1,574 shares of company stock valued at $2,398,888 in the last three months.

GlaxoSmithKline plc Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Analyst Recommendations for GlaxoSmithKline plc (LON:GSK)

What are top analysts saying about GlaxoSmithKline plc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GlaxoSmithKline plc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit